A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects With Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Pyrilutamide (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors Suzhou Kintor Pharmaceuticals
- 04 Aug 2021 New trial record